Abstract
Tyrosinemia type I is an autosomal recessively inherited metabolic disease of tyrosine metabolism due to the deficiency of fumarylacetoacetate hydrolase. Clinical manifestations include hepatic failure, cirrhosis, hepatocellular carcinoma, renal fanconi syndrome, and neurologic crisis. With the introduction of 2-(2-nitro-4-trifluoro-methylbenzyol)-1,3 cyclohexanedione treatment the prognosis improved with reduced rate of complications. “Neurologic crisis” of tyrosinemia type I is a rare complication seen after discontinuation of treatment characterized with anorexia, vomiting, and hyponatremia in the initial phase continuing with paresthesia and paralysis of the extremities and the diaphragm. Here, we report a tyrosinemia type I patient who admitted to the hospital with nonspecific symptoms such as vomiting, anorexia, weakness, and restlessness only after one month discontinuation of nitisone and diagnosed as neurological crisis.
References
Counce ML, Dalmau J, del Toro M, et al. (2011) Tyrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome. Pediatr Int 53:985–989
Jamieson GN, Jamieson N, Clayton P, Bailey S, Ryalls M, Barnes ND (1994) Neurological crisis in hereditary tyrosinaemia and complete reversal after liver transplantation. Arch Dis Child 70:544–545
Larochelle J, Alvarez F, Bussieres JF, et al. (2012) Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Quebec. Mol Genet Metab 107:49–54
Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B (1992) Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340:813–817
Nyhan WL, Barshop BA, Al-Aqeel AI (2012) Hepatorenal tyrosinemia/fumarylacetoacetate hydrolase deficiency. In: WL N, BA B, AI A-A (eds) Atlas of inherited metabolic diseases, Third edn. Hodder Arnold an Hachette UK Company, London, pp. 171–179
Rank JM, Pascual-Leone A, Payne W, et al. (1991) Clinical and laboratory observations. Hematin therapy for the neurologic crisis of tyrosinemia. J Pediatr 118:136–139
Schlump JU, Perot C, Ketteler K, et al. (2008) Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment. J Inherit Metab Dis 31(2):223–225
Zeybek AC, Kiykim E, Soyucen E, et al. (2015) Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience. Pediatr Int 57:281–289
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Önenli Mungan, N., Yıldızdaş, D., Kör, D. et al. Tyrosinemia type 1 and irreversible neurologic crisis after one month discontinuation of nitisone. Metab Brain Dis 31, 1181–1183 (2016). https://doi.org/10.1007/s11011-016-9833-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-016-9833-y